Clinical trials: Clinical Trial, Phase I
Solid Tumors
AS703569 Phase I in Patients With Solid Tumours
This is a Phase I trial. Some specific protocol information is proprietary and is not publicly available at this time. Full information will be provided to trial participants.
- Trial name
- NCT00391521
- Testing
- AS703569
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- EMD Serono
Refractory Cancer, Recurrent Cancer
IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors
The goal of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA402 in patients with recurrent and/or refractory solid tumors.
- Conditions
- Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult, Cancer
- Trial name
- NCT05958121
- Testing
- IMA402, IMA402 and checkpoint inhibitor, IMA402 and chemotherapy
- Where
- 29 sites in Germany, Netherlands
- Volunteers
- 400 people
- Sponsor
- Immatics Biotechnologies GmbH
Stage IV Melanoma
A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma
This study evaluates the effectiveness of adding a single four-day treatment of the fusion protein A-dmDT390-bisFv(UCHT1) - plus single palliative tumor radiation - with standard of care KEYTRUDA (Pembrolizumab) therapy for the…
- Trial name
- NCT02990416
- Testing
- A-dmDT390-bisFv(UCHT1), Pembrolizumab, Ionizing Radiation
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Virogen Biotechnology Inc.
Seasonal Influenza
Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (15µg/0.5ml)
The purpose of this study is to evaluate the safety and immunogenicity of quadrivalent influenza vaccine in healthy subjects aged over 3 years
- Trial name
- NCT03853993
- Testing
- Quadrivalent influenza vaccine, Trivalent influenza vaccine (contains B/Victoria strain), Trivalent influenza vaccine (contains B/Yamagata strain)
- Where
- 2 sites in China
- Volunteers
- 2,380 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
B Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia
CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL)
The purpose of this study is to test the safety and efficacy of AUTO3, a CAR T cell treatment targeting CD19 and CD22 in paediatric or young adult patients with relapsed or refractory B cell acute lymphoblastic leukaemia.
- Conditions
- B Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Refractory Childhood Acute Lymphoblastic Leukemia, B-cell Acute Lymphoblastic Leukemia
- Trial name
- AMELIA (NCT03289455)
- Testing
- AUTO3 (CD19/22 CAR T cells
- Where
- 3 sites in United Kingdom
- Volunteers
- 23 people
- Sponsor
- Autolus Limited
Advanced Solid Tumor
A Phase 1 Study of BB102 in Participants With Advanced Solid Tumors
This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, efficacy and preliminary food effect of BB102, a highly selective and potent FGFR4 inhibitor, as monotherapy in subjects with advanced solid tumors.
- Trial name
- NCT06258408
- Testing
- BB102 tablet
- Where
- 2 sites in China
- Volunteers
- 78 people
- Sponsor
- Broadenbio Ltd., Co.
Melanoma
PVSRIPO for Patients With Unresectable Melanoma
This study is a Phase I study of oncolytic polio/rhinovirus recombinant (PVSRIPO) to primarily characterize the safety and tolerability of PVSRIPO in patients with AJCC Stage IIIB, IIIC, or IV melanoma in a modified 3+3 phase 1…
- Trial name
- NCT03712358
- Testing
- PVSRIPO
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Istari Oncology, Inc.
Healthy
Bioavailability of BI 1356 Administered With and Without Food to Healthy Male and Female Subjects
To investigate the food effect on the relative bioavailability and pharmacokinetics of a 5 mg BI 1356 tablet administered as a single dose
- Trial name
- NCT02183493
- Testing
- BI 1356
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Pharmacokinetics
To Evaluate the Safety, Tolerability and Pharmacokinetic of SAL0133 Tablets in Chinese Adult Healthy Subjects
To evaluate the safety and tolerance of single and multiple administrations of SAL0133 tablets in adult healthy subjects in China receptivity.
- Trial name
- NCT07030504
- Testing
- SAL0133
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Leukemia, Myeloid, Acute
BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment
Investigation of maximum tolerated dose, safety, efficacy and pharmcokinetics of BI 811283 in combination with cytarabine (LD-Ara-C) in previously untreated acute myeloid leukaemia (AML) patients
- Trial name
- NCT00632749
- Testing
- BI 811283 (d 1 and 15), Cytarabine, BI 811283 (d1)
- Where
- 7 sites in Germany
- Volunteers
- 68 people
- Sponsor
- Boehringer Ingelheim
Advanced Solid Tumors
A Phase I Clinical Study of the Safety， Tolerability，Pharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid Tumors
The study is being conducted to evaluate the efficacy, andsafety of HRS-6209in subjects with advanced solid tumors.To explore the reasonable dosage of HRS-6209.This study also preliminarily evaluated the efficacy of HRS-6209 in…
- Trial name
- NCT05781048
- Testing
- HRS-6209
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Advanced Solid Tumors, Lymphoma
Phase I Trial of PX-478
This study is being conducted to determine the safety and biologic activity of PX-478, and to allow for observation of any preliminary evidence of antitumor activity in patients with advanced metastatic cancer.
- Trial name
- NCT00522652
- Testing
- PX-478
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Cascadian Therapeutics Inc.
Cancer, Neoplasms
Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors
This research is designed to determine if experimental treatment with PARP1 inhibitor, VB15010 is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.
- Conditions
- Cancer, Neoplasms, Neoplasms, Breast, Tumor
- Trial name
- NCT06819215
- Testing
- VB15010
- Where
- China
- Volunteers
- 188 people
- Sponsor
- Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
Uterine Cervical Neoplasms, Cervix Intraepithelial Neoplasia
Safety and Tolerability of Cidofovir Gel Applied on Cervix Squamous Lesions
Human Papilloma Virus (HPV) infections induce cervical intraepithelial neoplasia (CIN) of cervix. To reduce incidence of invasive tumor associated with high grade CIN lesions, the standard treatment is the conisation of cervix…
- Trial name
- NCT00989443
- Testing
- Cidofovir gel
- Where
- Belgium
- Volunteers
- 6 people
- Sponsor
- Mithra Pharmaceuticals
Healthy
Sudapyridine (WX-081) in Healthy Volunteers
The objective of this study is to evaluate the safety, tolerability as well as pharmacokinetics of Sudapyridine (WX-081) in Chinese volunteers.
- Trial name
- NCT06117514
- Testing
- Sudapyridine 30mg, Sudapyridine 100mg SAD, Sudapyridine 200mg SAD
- Where
- China
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Shanghai Jiatan Pharmatech Co., Ltd
Solid Tumors
A Phase 1 Study of HDM2017 in Advanced Solid Tumors
This is a phase I clinical study. All subjects are patients with advanced solid tumors. The purpose of this study is to to evaluate the safety, tolerability, pharmacokinetic (PK) characteristics, and preliminary antitumor…
- Trial name
- NCT07274085
- Testing
- HDM2017
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Advanced Solid Tumors
The Tolerability and Pharmacokinetics of HX301 Monolactate Capsules in Patients With Advanced Solid Tumors
Open label, single- and multiple-dose administration, dose-exploratory clinical phase I study to evaluate the safety, tolerability and PK profile of HX301 monolactate capsules in patients with advanced malignant solid tumors and…
- Trial name
- NCT05731934
- Testing
- HX301
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Hangzhou Hanx Biopharmaceuticals, Ltd.
Rheumatoid Arthritis
A Clinical Trial of Safety and Tolerance of TQH3821 Tablets in Adult Healthy Subjects
This study was a randomized, double-blind, placebo-controlled phase I clinical trial of TQH3821 in adult healthy subjects, which plans to recruit 72 healthy subjects.
- Trial name
- NCT05380934
- Testing
- TQH3821 tablets, Methotrexate tablets
- Where
- China
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Solid Tumors
VBC117First-in-Human Trial of VBC117 in Participants With Advanced Malignant Solid Tumors
Detailed Description: This is a multicenter, open-label, multiple-dose, first in human(FIH) Phase 1/2a trial. The Phase 1 portion uses the Bayesian optimal interval (BOIN) design to escalate doses and determine the maximum…
- Trial name
- NCT07772934
- Testing
- VBC117
- Where
- 12 sites in Australia, China
- Volunteers
- 260 people
- Sponsor
- VelaVigo Bio Inc
Healthy
Safety, Tolerability and Pharmacokinetics of EB-203 Eye Drops in Healthy Volunteers
The purpose of study is to evaluate safety, tolerability and pharmacokinetics of EB-203 Drops in adult healthy volunteers. condition/disease : AMD(Age-related Macular Degeneration) Intervention/treatment : EB-203 or Placebo Phase…
- Trial name
- NCT05538949
- Testing
- EB-203
- Where
- South Korea
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- EyebioKorea, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.